scholarly journals BrainSeq: Neurogenomics to Drive Novel Target Discovery for Neuropsychiatric Disorders

Neuron ◽  
2015 ◽  
Vol 88 (6) ◽  
pp. 1078-1083 ◽  
Author(s):  
Christian R. Schubert ◽  
Patricio O’Donnell ◽  
Jie Quan ◽  
Jens R. Wendland ◽  
Hualin S. Xi ◽  
...  
Keyword(s):  
Neuropsychiatric Disorders ◽  
Target Discovery ◽  
Novel Target

Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Alpha as a Novel Target for Bipolar Disorder and Other Neuropsychiatric Disorders

2018 ◽  
Vol 83 (9) ◽  
pp. 761-769 ◽  
Author(s):  
Andrew A. Nierenberg ◽  
Sharmin A. Ghaznavi ◽  
Isadora Sande Mathias ◽  
Kristen K. Ellard ◽  
Jessica A. Janos ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Neuropsychiatric Disorders ◽  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor ◽  
Novel Target

Antisense Antibiotics: A Brief Review of Novel Target Discovery and Delivery

2010 ◽  
Vol 7 (2) ◽  
pp. 76-85 ◽  
Author(s):  
Hui Bai ◽  
Xiaoyan Xue ◽  
Zheng Hou ◽  
Ying Zhou ◽  
Jingru Meng ◽  
...  
Keyword(s):  
Target Discovery ◽  
Novel Target

scholarly journals Glo1 inhibitors for neuropsychiatric and anti-epileptic drug development

2014 ◽  
Vol 42 (2) ◽  
pp. 461-467 ◽  
Author(s):  
Katherine M.J. McMurray ◽  
Margaret G. Distler ◽  
Preetpal S. Sidhu ◽  
James M. Cook ◽  
Leggy A. Arnold ◽  
...  
Keyword(s):  
Therapeutic Potential ◽  
Partial Agonist ◽  
Neuropsychiatric Disorders ◽  
Anxiety And Depression ◽  
Glyoxalase I ◽  
Pharmacological Treatments ◽  
Delayed Onset ◽  
Anti Epileptic Drug ◽  
Novel Target ◽  
Target Effects

Many current pharmacological treatments for neuropsychiatric disorders, such as anxiety and depression, are limited by a delayed onset of therapeutic effect, adverse side effects, abuse potential or lack of efficacy in many patients. These off-target effects highlight the need to identify novel mechanisms and targets for treatment. Recently, modulation of Glo1 (glyoxalase I) activity was shown to regulate anxiety-like behaviour and seizure-susceptibility in mice. These effects are likely to be mediated through the regulation of MG (methylglyoxal) by Glo1, as MG acts as a competitive partial agonist at GABAA (γ-aminobutyric acid A) receptors. Thus modulation of MG by Glo1 represents a novel target for treatment. In the present article, we evaluate the therapeutic potential of indirectly modulating MG concentrations through Glo1 inhibitors for the treatment of neuropsychiatric disorders.

Abstract 1142: Novel target discovery for glioblastoma using chemical biology fingerprinting

2017 ◽  
Author(s):  
Darren Finlay ◽  
Pedro Aza-Blanc ◽  
Harshil Dhruv ◽  
Alexey Eroshkin ◽  
Craig Hauser ◽  
...  
Keyword(s):  
Chemical Biology ◽  
Target Discovery ◽  
Novel Target

FEATURES

2011 ◽  
Vol 15 (12) ◽  
pp. 15-31 ◽  
Keyword(s):  
Drug Discovery ◽  
South Korea ◽  
Research Center ◽  
Target Discovery ◽  
Current State ◽  
Novel Target

Biorefinery Research in Korea. Genomics and Bioinformatics in Korea. Current State of Biomass Technology (BmT) Research in South Korea: Advanced Biomass R&D Center (ABC). Medicinal Bioconvergence Research Center: Innovation of Drug Discovery through Novel Target Discovery and Convergence Technology.

MHC-bound antigens and proteomics for novel target discovery

2004 ◽  
Vol 5 (7) ◽  
pp. 845-859 ◽  
Author(s):  
Stacy H Shoshan ◽  
Arie Admon
Keyword(s):  
Target Discovery ◽  
Novel Target
Sign in / Sign up

Export Citation Format

Share Document